Soleno Therapeutics, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced that it has signed a collaboration agreement with Vanderbilt University aiming to discover and develop novel KATP channel activators with the potential to treat rare diseases. The collaboration will be led by Drs. Craig Lindsley and Jerod Denton.
The initial aims of this collaboration are to develop robust in vivo and in vitro tools to identify and characterize novel KATP channel activators from recently identified new classes of chemistry. Soleno expects to advance appropriate candidates generated from this collaboration into the clinic in the future.
Activating KATP channels has been shown to be beneficial in the treatment of various rare diseases, such as hyperinsulinemic hypoglycemia. Soleno’s lead candidate, DCCR (diazoxide choline tablets), is a potent activator of KATP channels and has demonstrated significant benefits in a Phase 3 study for the treatment of Prader-Willi syndrome (PWS). Diazoxide choline has received Orphan Drug Designation for the treatment of PWS in the U.S. and EU, and Fast Track Designation in the U.S.